InsiderSignal.AI

InsiderSignal.ai

LQDA - Liquidia Corp

Insider Sale by Boyle Dana (Chief Accounting Officer)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

4 days ago, Boyle Dana, serving as Chief Accounting Officer at Liquidia Corp (LQDA), sold 1,576 shares at $37.78 per share, for a total transaction value of $59,541.00. Following this transaction, Boyle Dana now holds 175,342 shares of LQDA.

This sale represents a 1.00% decrease in Boyle Dana's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Monday, April 27, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, April 29, 2026, 2 days after the trade was made.

Liquidia Corp operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Boyle Dana

Boyle Dana

Chief Accounting Officer

Dana Boyle is the Chief Accounting Officer at Liquidia Corporation (LQDA), appointed to the role on July 1, 2025.[[1]](https://www.tipranks.com/news/company-announcements/liquidia-technologies-appoints-dana-boyle-as-chief-accounting-officer)[[2]](https://www.investing.com/news/sec-filings/liquidia-appoints-dana-boyle-as-chief-accounting-officer-93CH-4120044) Previously, she served as Senior Vice President of Finance and Controller at Liquidia since January 2021.[[1]](https://www.tipranks.com/news/company-announcements/liquidia-technologies-appoints-dana-boyle-as-chief-accounting-officer)[[2]](https://www.investing.com/news/sec-filings/liquidia-appoints-dana-boyle-as-chief-accounting-officer-93CH-4120044)[[3]](https://www.insidertrades.com/liquidia-co-stock/dana-boyle/) Boyle, aged 41, brings over 20 years of experience in accounting, financial planning, and analysis within the life sciences sector.[[2]](https://www.investing.com/news/sec-filings/liquidia-appoints-dana-boyle-as-chief-accounting-officer-93CH-4120044)[[3]](https://www.insidertrades.com/liquidia-co-stock/dana-boyle/) Her prior roles include Controller at Aerami Therapeutics (2019-2021) and Director of Financial Planning and Analysis at Aralez Pharmaceuticals (2017-2018), with earlier positions at Iveric Bio and a start in Audit & Assurance and Mergers & Acquisitions at Deloitte & Touche LLP.[[2]](https://www.investing.com/news/sec-filings/liquidia-appoints-dana-boyle-as-chief-accounting-officer-93CH-4120044)[[3]](https://www.insidertrades.com/liquidia-co-stock/dana-boyle/) She holds a Bachelor of Science in accounting from Rutgers University and is a Certified Public Accountant (CPA) licensed in New York.[[2]](https://www.investing.com/news/sec-filings/liquidia-appoints-dana-boyle-as-chief-accounting-officer-93CH-4120044)[[3]](https://www.insidertrades.com/liquidia-co-stock/dana-boyle/) As of early 2026, Boyle owns approximately 178,848 shares of Liquidia stock, valued at over $6 million, and recently sold shares totaling $479,296 in the prior ninety days.[[3]](https://www.insidertrades.com/liquidia-co-stock/dana-boyle/)

View full insider profile →

Trade Price

$37.78

Quantity

1,576

Total Value

$59,541.00

Shares Owned

175,342

Trade Date

Monday, April 27, 2026

4 days ago

SEC Filing Date

Wednesday, April 29, 2026

Filed 2 days after trade

HEALTHCAREBIOTECHNOLOGY

Discussion

Sign in to join the discussion.
Loading comments…
View news mentioning LQDA

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/6051558

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime